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Bone marrow failure disorders (BMFDs), which are characterized by an early pro-apoptotic phase which results 
in faulty hematopoiesis and anemia, more often than not progress to outright acute myelogenous leukemia 
(AML). Recent findings have indicated that most if not all of these disorders have a very significant RNA 
processing component to their pathology. This review aims to highlight some of normal processes of RNA 
metabolism that have been recently demonstrated to be altered in BMFDs. 
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Introduction 
Bone marrow failure disorders (BMFDs) are a 
heterogeneous and insidious group of hematological diseases 
whose symptoms inevitably include a mono- or 
pan-cytopenia with an elevated risk of developing acute 
myelogenous leukemia (AML), but these disorders may also 
involve other tissues outside the hematologic compartment. It 
is believed that bone marrow failure is the most characteristic 
symptom of these disorders, because it is the bone marrow 
and hematologic compartment the undergoes the most cell 
turnover and proliferation during the human lifespan making 
them more vulnerable [1]. The BMFDs are divided into two 
main groups, acquired and hereditary.  
Acquired bone marrow failure disorders namely include 
myelodysplastic syndromes (MDS) and aplastic anemia (AP) 
where no known hereditary alteration is directly responsible 
for the development of the disorder [2]. These acquired 
disorders often arise later in life (>60 years of age; MDS) or 
following exposure to some form of cytotoxic stress, such as 
environmental toxins or chemotherapy. In contrast, 
hereditary bone marrow disorders involve the inherited 
mutation of a single gene or one of several related genes [1].  
In all BMFDs, acquired and hereditary, there is a phase of 
intense selective pressure on the hematopoietic stem cell 
population resulting in enhanced apoptosis and inflammation 
(including the presence of cytotoxic cytokines) in the bone 
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marrow and mono- to pancytopenias in the periphery. In the 
case of MDS and FA, it has been clearly demonstrated that 
this phase is replaced over time by an anti-apoptotic phase 
where the hematopoietic progenitor cells lose their sensitivity 
to apoptotic stimuli [1-3]. This is often followed by the 
increased presence of immature hematopoietic progenitors in 
the periphery and the subsequent development of leukemia [2, 
3]. 
The initial recognition of oncogenes/protooncogenes as 
causative agents in cancer and the identification of mutations, 
rearrangements, and altered expression of these same genes 
first focused major attention on the particular genes (ex. 
BCR-ABL in chronic myelogenous leukemia, CML). In 
reality, unlike CML, very few de novo cancers can be 
directly linked to alterations in known oncogenes. While 
some genetic alterations are repeatedly observed in certain 
cancers, the cancer of no two patients is the same. Later 
theories involved identification of cancer stem cells, or those 
cells that can give rise to tumors. Interestingly, cancer stem 
cells are more resistant to stress and therapy [4]. Recent data 
from bone marrow failure disorders, namely Fanconi anemia 
and MDS, have indicated that in hematological 
pre-malignancies that often give rise to AML, there is a 
process of natural selection taking place in the bone marrow 
[1-3]. Exposure to chronic stress and inflammation or 
hypersensitivity to inflammatory mediators (TNFα, IL-1α, 
IFNγ) promotes the growth suppression and apoptosis of 
hematopoietic progenitors in the bone marrow. Thus, HSCs 
and progenitors that survive and proliferate have, over time, 
acquired random gain of function mutations, leaving them 
with characteristics of cancer stem cells. This same process 
may explain the role of chronic stress and inflammation and 
the tight association of the innate immune system with 
cancer [2, 3]. 
While the selective pressures exerted in the bone marrow 
may favor random gain of function mutations, many of these 
alterations have a gross impact on RNA processing, splicing 
and ribosome biogenesis. This review aims to cover recent 
findings BMFDs that suggest altered RNA processing maybe 
at the heart of the selective (apoptotic) phase of BMFDs but 
may also facilitate the progression to AML. 
Acquired bone marrow failure disorders 
Acquired bone marrow failure disorders are those where 
no known hereditary alteration is directly responsible for the 
development of the disorder and typically occur later in life. 
As such, the initial cause of the disorder is not known but 
seems to heavily involve an immune component, either 
innate immune/inflammatory or autoimmune [5-7]. Acquired 
BMFDs namely include MDS AP. 
Myelodysplastic syndromes (MDS) 
Myelodysplastic syndromes are a heterogeneous group 
hematological malignancies that result in cytopenias in one 
or more of the hematologic lineages, with or without 
cytogenetic abnormalities. De novo MDS typically occurs in 
later life (>60 years of age) and is thus considered an 
age-related disorder. In contrast, MDS can also arise from the 
progression of other hematological malignancies including 
BMFDs. Moreover, therapy-related MDS (tMDS) is known 
to occur in individuals previously treated with 
chemotherapeutic agents for diverse types of cancer [7].  
MDS is categorized by the International Prognostic 
Scoring System (IPSS) as low, intermediate-1, 
intermediate-2 and high based on the risk of the disease 
progressing to acute leukemia. In low-risk disease there is a 
propensity for hematologic stem cells and progenitors to 
undergo apoptosis with few blasts observed in the peripheral 
blood. This is gradually replaced during disease progression 
from low- to high-risk, where there is hypercellularity of the 
bone marrow and the appearance of blasts in the periphery [6, 
7].  
Diverse groups have demonstrated a role for 
stress/inflammatory signaling during progression of MDS to 
AML [2, 8, 9]. More recently, significant alterations in DNA 
methylation, chromatin modification, transcriptional 
regulation, DNA repair, signal transduction, sister chromatid 
cohesion and RNA splicing and ribosome biogenesis 
associated genes have been observed. Mutations in RNA 
splicing/processing genes are estimated to be present in 
45-85% myelodysplasias [10]. Diverse groups have observed 
mutations in serine/arginine-rich splicing factor (SRSF)-2, 
splicing factor 3B subunit 1 (SF3B1), spicing factor U2AF 
35 kDa subunit (U2AF35) and U2 small nuclear 
ribonucleoprotein auxiliary factor 35 kDa subunit related 
protein 2 (ZRSR2). Certain mutations are specific to 
particular subtypes of myelodysplasia [10-12].  
Aplastic anemia 
The cause of aplastic anemia is not well understood, but it 
is believed to result from a hyperactive immune response to 
the bone marrow [5]. As such the onset of aplastic anemia is 
rapid and devastating creating a pancytopenia. Without 
proper treatment, affected individuals usually succumb to the 
disease in a matter of months. Environmental exposure to 
pesticides and chemicals, as well as certain viral infections 
have been linked to the development of aplastic anemia, but 
is ultimately the unresolved immune attack of the bone 
marrow and hematopoietic progenitors involving cytotoxic 
T-lymphocytes and cytotoxic cytokines such as interferon 
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(IFN)-γ and tumor necrosis factor (TNF)-α that give rise to 
the disease symptomology [5, 13]. It should be noted that 
aplastic anemia, like MDS, can arise from a 
pre-existing/congenital condition such as a hereditary 
BMFD. Treatment usually consists of 
anti-inflammatory/steroids or bone marrow transplantation. 
Individuals who survive one bout of aplastic crisis are at an 
elevated risk (~50%) to experience another attack and/or, 
through clonal selection, to develop MDS and AML [5]. Thus, 
many of the alterations seen in surviving aplastic anemia 
patients tend to be those same alterations observed in MDS 
and AML (see above). 
Hereditary bone marrow failure disorders 
Hereditary bone marrow disorders which include: Fanconi 
anemia (FA), Diamond-Blackfan anemia (DBA), 
Shwachman-Diamond syndrome (SDS), Dyskeratosis 
congenital (DC), Kostmann syndrome (SCN) and 
Amegakaryocytic Thrombocytopenia (AT). All involve the 
presence of an inherited mutation in one particular gene 
(SDS, AT) or one of a set of genes involved in a common 
cellular process (FA, DBA, DC, SCN), which is ultimately 
responsible for the observed disease phenotype [1]. In those 
BMFDs where a mutation in more than one gene can causes 
the same disease, the pattern of inheritance and the 
penetrance of the disease phenotype may vary greatly.  
While the hereditary BMFDs and individuals that have 
survived a bout of aplastic anemia show increased risk for 
the development of MDS, individuals with any bone marrow 
failure disorder demonstrate an elevated risk for the 
development of AML [1, 5]. Interestingly, it is this 
characteristic of progressing from a pro-apoptotic state to a 
pro-proliferative one that has modified the cancer stem cell 
theory and begun to revolutionize the way in which cancer as 
a disease is perceived to develop, by introducing the 
principle of clonality [3, 6]. Clonality is the offspring of 
natural selection occurring in the bone marrow in response to 
the chronic presence of innate immune/stress/inflammatory 
signaling. 
Fanconi anemia 
Fanconi anemia is a rare, congenital, recessive disorder 
characterized by diverse overt abnormalities (microcephaly, 
microphthalmia, abnormal tumbs and radii, and slow growth) 
as well as unexplained cytopenias and early onset of 
myelodysplasia, aplastic anemia, or AML. Affected 
individuals may also present with head-and-neck, esophageal 
and gynecological cancers at an atypically young age [1, 14]. 
Fanconi anemia can arise from the mutation of any of 
approximately 21 known genes and cases are grouped based 
on the gene mutated. The majority of FA patients fall into 
groups A, C or G with respective mutation in the FANCA, 
FANCC or FANCG genes.  Individually, the encoded FA 
proteins carry-out diverse functions in metabolism, oxidative 
stress, cellular signaling and transcriptional regulation to 
name a few, but together they either form the core complex 
required for double-strand DNA break repair or are essential 
for its regulation [14]. As such, FA patients are hypersensitive 
to DNA damaging agents, especially DNA cross-linking 
agents such as mitomycin C. In addition, bone marrow stem 
cells and early progenitors are hypersensitive to the effects 
TNFα and IFNγ, and demonstrate elevated innate 
immune/inflammatory signaling similar to chronic 
inflammation [2, 14, 15]. As these patients begin to progress to 
MDS and AML, there is a concurrent loss of sensitivity to 
the same cytotoxic stresses the bone marrow stem cells and 
hematopoietic progenitors were previously hypersensitive, 
again pointing to clonal evolution [2, 3, 9, 15, 16].  
While unlike many of the other congenital BMFDs, genes 
mutated in FA have no known direct link to RNA 
splicing/processing (although DNA damage may favor 
alternate splicing of RNAs encoding proteins that aid in the 
damage response), their effects on DNA damage repair 
predispose the cell to accumulate mutations in other genes, 
including those involved in RNA processing. In addition, the 
constitutive activation of PKR which is known to interact 
with intermediates of RNA processing, including splicing 
factors, ribosomal proteins, RNA helicases and 
ribonucleoproteins, may select for survival alterations in 
these intermediates [17]. Thus, it may be inferred that the 
alteration in RNA processing and splicing genes in MDS 
represents a compensatory result of clonal selection which 
favors survival.  
Diamond-Blackfan anemia (DBA) 
Diamond-Blackfan Anemia (DBA) is a rare congenital 
bone marrow failure disorder often noted within the first year 
or two after birth. DBA is mainly characterized by a 
profound anemia, but like FA, other congenital defects 
(growth retardation, cranialfacial abnormalities, defects in 
the heart and urinary system) are observe in a significant 
portion of patients (up to 50%). These individuals have an 
increased incidence of developing MDS and AML as well as 
some other forms of cancer [1, 18]. DBA appears to result from 
altered ribosomal RNA (rRNA) processing which, in turn, 
affects ribosome biogenesis of the 40S and 60S ribosomal 
subunits and alters mRNA processing/transport and 
translation; thus having pleiotropic effects on cellular growth 
and survival [18].   
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To date, DBA has been associated with diverse mutations 
in the following ribosomal proteins: RPS7, RPS10, RPS17, 
RPS19, RPS24, RPS26, RPS27, RPS29, RPL5, RPL11, 
RPL26, RPL27, RPL35A and deletion of RPL15; and other 
novel mutations have been reported in RPL3L, RPL6, 
RPL7L1T, RPL8, RPL13, RPL14, RPL18A and RPL31. 
Approximately 50% of DBA patients contain mutations in 
RPS7, RPS10, RPS17, RPS19, RPS24, RPS26, RPS29, 
RPL5, RPL11, RPL26, RPL35A or GATA. Mutations in 
RPS19 alone account for ~25% of these patients [19]. The 
other 50% of cases have no yet identified mutation, but are 
almost assuredly mutations associated with pre-rRNA 
processing and ribosome assembly.  
There is some evidence that altered ribosome biogenesis 
may induce an inflammatory component. In patients bearing 
a RPS19 deficiency, the levels of GATA1 were found to be 
reduced in the erythroid progenitor population while p53 and 
TNFα expression were increased in the non-erythroid 
progenitors [18, 20]. Inhibition of TNFα in a zebrafish model of 
RPS19-deficiency was able to rescue the observed anemia, 
suggesting TNFα expression has a significant role in the 
observed phenotype [20]. 
Shwachman-Diamond Syndrome (SDS) 
Shwachman-Diamond syndrome is an autosomal recessive 
disorder which initially manifests as an exocrine pancreatic 
dysfunction but then results in bone marrow failure and 
skeletal abnormalities. Approximately 20% of SDS patients 
will progress to MDS while another 25% will develop AML 
[1]. In almost all cases (~90%), patients carry a mutation in 
the Shwachman-Blackfan-Diamond syndrome (SBDS) gene. 
This protein is required for the proper maturation and nuclear 
export of the 60S ribosomal subunit to which it is often 
found associated [1, 21]. In addition to the 60S ribosomal 
subunit, SBDS has also been found in association with 28S 
rRNA and nucleophosmin (NPM) [21]. The general consensus 
is that mutations in SBDS result in altered 60S ribosome 
biogenesis and an enhanced sensitivity to stress. 
Dyskeratosis congenita (DC) 
Dyskeratosis congenital (DC) is a highly rare multi-system 
progressive bone marrow failure disorder that can either 
present an autosomal dominant, autosomal recessive or 
X-linked inheritance pattern base or the causative mutation. 
Its penetrance can vary widely extending from barely 
detectible to severe as in the case of Hoyeraal Hreidarson 
syndrome [1, 22]. Dyskeratosis presents with a triad of 
symptoms which include, reticulated skin 
hyperpigmentation, nail dystrophy and mucosal leukoplakia 
and results in premature death resulting from bone marrow 
failure, respiratory dysfunction or malignancy.  
While dyskeratin (DKC1), which encodes for a protein 
involved both in the small nucleolar ribonucleoprotein 
(H/ACA snoRNP) and in the telomere complexes, and whose 
mutation is responsible for the X-linked form of DC, is by far 
the better studied; other proteins involved in the H/ACA 
snoRNP complex (NOP10 and NHP2), the telomerase 
ribonucleoprotein complex shelterin (TINF2); TERT, the 
telomerase reverse transcriptase; TERC, which encodes the 
RNA component of TERT and whose mutation is responsible 
for the autosomal dominant form of DC; WRAP53, which 
delivers TERC to the telomerase as well as binds Cajal body 
RNAs (scaRNAs) and regulates p53 mRNA levels 
post-transcriptionally; RTEL1, which is involved in telomere 
elongation; and CTC1, a subunit of the CTC complex which 
terminates TERT activity and recruits DNA polymerase for 
complement strand synthesis, are also implicated [1, 22]. All 
these proteins are involved in telomere maintenance, while 
several are also directly involved in small ribonuclear RNA 
processing, resulting in pseudouridylation of the snRNAs. It 
is still not clear as to whether alterations in the telomerase 
complex itself is the underlying cause of DC or whether 
telomere shortening in DC patients also has a major 
component linked to processing of RNAs required for the 
telomerase complex [23, 24]. As might be expected tissues with 
the greatest proliferative/turn-over rates are the most affected 
by DC.   
RNA processing 
RNA processing refers to many aspects of RNA 
metabolism including, splicing (alternative splicing), 
post-transcriptional nucleotide modifications (methylation, 
pseudouridylation, deamination), folding, stability, 
degradation, cellular localization and transport. A large 
number of cellular proteins and RNAs are dedicated to these 
processes, and alteration of any of these may result in 
disease. The following sections aim to examine the role of 
RNA processing defects in bone marrow failure disorders by 
examining the role of the diverse proteins altered in these 
hematopoietic disorders in RNA processing. 
mRNA splicing 
In eukaryotic cells, the splicing of exons to remove the 
introns is mandatory for the proper synthesis of mature 
mRNA transcripts and their encoded proteins [25, 26]. In the 
nucleus the pre-mRNA or primary transcript enters its first 
post-transcriptional modification through the association of 
the spliceosome complex. Splicing requires both cis- and 
trans-acting factors. The cis-acting factors consist of RNA 
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sequences 5’ and 3’ of the intron-exon junction and the 
branch-point region located near the 3’ splice site. In addition 
to these, sequences present in the introns and exons serve as 
splicing enhancers or silencers. The trans-acting factors 
consist of the small nuclear ribonucleoproteins snRNPs U1, 
U2, U4/6 and U5 as well as close to 300 additional proteins 
[25, 26].  
Splicing initiates with the ATP-dependent binding of U1 
snRNP to the 5’ splice site of the intron. This interaction is 
stabilized by members of the serine/arginine-rich (SR) 
protein family. At the same time, the SF1/BBP protein and 
the U2 auxiliary factor (U2AF) associate with the branch 
point region at the 3’-end. The 35-kDa subunit of the U2AF 
heterodimer binds to the 3’ splice site, while the 65-kDa 
subunit of U2AF serves to bridge the SF1/BBP and 35-kDa 
subunit of U2AF. This initial recognition of the 5’ and 3’ 
splice sites forms what is referred to as the E-complex [26]. At 
this point the U2 snRNP associates in an ATP-dependent 
manner with the break point region forming the A-complex 
and is stabilized by the association of SF3 (A and B) proteins 
as well as U2AF. SF1/BBP is displaced and replaced by 
other SF3 proteins. A pre-assembled U4/U6/U5 complex is 
then recruited to the A-complex to form the B-complex. 
Structural alteration of the spliceosome results in the 
destabilization of the U1 and U4 interactions and these 
snRNPs are lost resulting in an active spliceosome complex 
or B’-complex which initiates the first catalytic step of 
splicing to form the C-complex [26]. The second catalytic step 
in splicing occurs through structural modification of the 
spliceosome RNP component, which may associate or 
disassociate from complex. The final phase results in the 
release of U2, U5 and U6 snRNPs and the release of the 
spliced mRNA and intron [26]. This process sequentially 
occurs to form the mature mRNA, but in some cases not all 
introns are removed or not every exon is included to form the 
final mRNA. This is often a result of alternative splicing.  
Alternative splicing of mRNA is a fundamental process to 
enhance the possibility of gene expression and increase 
protein diversity, where numerous interacting components of 
the spliceosome complex and associated hetronuclear RNPs 
(hnRNPs) are involved with cis-acting elements in the 
primary transcript. Any impairment of this mechanism is 
associated with failure of normal cellular function with a 
final outcome of disease [27]. It is becoming more evident that 
for a majority of genes one single primary transcript strand 
does encode only a single protein but rather diverse isoforms 
of the same protein, each having specific functions in given 
tissues. Not only can alternative splicing affect the amino 
acid sequence of the resulting protein, affecting its 
function/activity or localization, but it can also influence the 
translation efficiency and stability of the encoding mRNA 
and thus regulate protein expression post-transcriptionally 
but pre-translationally. This mechanism is finely regulated at 
developmental stages in different tissues, and an alteration in 
regulation of alternative splicing is now linked with several 
human diseases, including leukemia and pre-leukemic states 
such as MDS [28]. Recent findings of frequent mutations of 
gene involved in RNA splicing in myelodysplasia has, 
therefore, identified a significant event that highlights how 
cancer develops by targeting critical cellular functions during 
the process of clonal selection [29]. It also gives an interesting 
view into the mechanism of cancer specific alternative 
splicing [30]. Evidence exists implicating splicing factor 
mutations as founder mutations in MDS and having a role in 
MDS progression to AML [31-33]. SF3B1, U2AF1, SRSF2 and 
ZRSR2 are splicing factors that carry recurrent somatic 
mutations in MDS and are components of the E/A splicing 
complex that coordinates 3’ splice site recognition during the 
early phase of pre-mRNA processing [10, 34, 35]. Alternative 
splicing may be the point of departure for the discovery of 
novel diagnostic and prognostic biomarkers and more than 
that for new therapeutic strategies of diseases, primarily 
cancer.  
Serine/Arginine-rich splicing factors (SRSFs) 
The serine/arginine (SR) splicing factor family is 
comprised of 12 phylogenetically conserved and structurally 
related proteins involved in the control of constitutive and 
alternative pre-mRNA splicing, as well as in other aspects of 
gene expression [36]. SRSFs contain one or two 
RNA-recognition motif at the N-terminus and one SR 
domain, which serves as an intermediary in the interaction 
with other proteins, at the C-terminus [36]. SRSF1 and 
SRSF2, which have been extensively investigated, serve 
pivotal roles in cell cycle regulation, genome stability, 
translation and pre-mRNA splicing [37].  
Activity of the SR proteins is highly regulated by 
extensive and reversible phosphorylation of serine residues 
carried-out by CDC-like kinase (CLKs), SRSF protein kinase 
(SRPKs), and pre-mRNA splicing 4 kinase (PRP4K). These 
phosphorylations modulate protein–protein interactions 
within the spliceosome and regulate the activity and 
sub-cellular distribution of SR proteins. Therefore, changes 
in the phosphorylation state of SR proteins during growth 
factor/cytokine stimulation or stress (inflammation, cytotoxic 
cytokines) play a critical role in the control of their activity 
[36, 38].   
Somatic mutations involving core components of the RNA 
splicing machinery have been detected in myelodysplastic 
syndrome (MDS). SRSF2, one of the SR proteins composed 
of a RNA recognition motif (RRM) domain and a RS 
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domain, frequently binds to splicing enhancer sequences 
(SES) and acts as a general splicing activator. In addition, 
SRSF2 is involved in transcriptional activation, RNA 
stability, mRNA transport, and mRNA translation [39]. 
Moreover, SRSF2 also has a role in the regulation of DNA 
stability; in fact, loss of SC35 in mouse embryonic 
fibroblasts induces G2/M cell cycle arrest and genomic 
instability, consequent at least in part from p53 
hyperphosphorylation and hyperacetylation [40]. 
Heterozygous mutations in SRSF2 are common in patients 
with myelodysplastic syndromes (MDS) and chronic 
myelomonocytic leukemia (CMML) and are associated with 
adverse prognosis. The most frequent mutation that occurs in 
SRSF2 affects its binding affinity and induces abnormal 
splicing of primary hematopoietic regulators [41-43].  
Thol et al., reported that in an analysis of 193 MDS 
patients, mutations are present in at least 1 of the investigated 
genes involved in the splicing machinery (i.e., SRSF2, 
U2AF1, ZRSR2, and SF3B1) in 34.7% of all investigated 
patients, suggesting mutations in genes that encode proteins 
involved in the splicing pathway are common in MDS. 
Mutations in SF3B1 and SRSF2 were the most prevalent 
aberrations identified in MDS patients; SRSF2 mutations 
were also associated with a negative prognostic impact [44]. 
SRSF2, U2AF1, and ZRSR2 mutations were present in all 
subtypes of MDS and were not associated with a specific 
IPSS risk profile or cytogenetic aberration. In this study, the 
authors also presented evidence that mutations in SRSF2 are 
related with mutations in RUNX1, a member of the core 
binding factor family of transcription factors and one of the 
most frequently mutated genes in a variety of hematological 
malignancies, as well as IDH1, the gene coding for isocitrate 
dehydrogenase, an enzyme of the citric acid cycle; thus 
stabilizing a link with metabolism and the mitochondria [44].  
Splicing factor 3B1 (SF3B1) 
SF3B complex is a constituent of the essential U2 snRNP 
splicing factor [26]. The SF3B1 protein is one of seven 
subunits (SF3B1-5, SF3B14 and PHF5A) of the SF3B 
complex [45]. Unlike SRSFs, SF3B1 mutations are associated 
with specific subtypes of MDS. Mutations in SF3B1 
abrogate the role of different genes related to mitochondrial 
metabolism and they are found in a high percentage 
(70-90%) of MDS patients whose disease is characterized by 
the presence of ring sideroblasts, including both refractory 
anemia with ring sideroblasts (RARS) and refractory 
cytopenia with multilineage dysplasia and ring sideroblasts. 
Thus, patients harboring SF3B1 mutations present an 
increased number of ringed sideroblasts due to impaired 
synthesis of heme [11, 46].  
SF3B1 mutations are generally more prevalent in low-risk 
MDS and have been shown to be independent predictors of 
favorable clinical outcome in MDS [46]. It has been shown 
that SF3B1 knockdown in four myeloid cell lines resulted in 
inhibition of cell growth and disruption of the cell cycle [47].  
Recently, Paolella et al. found that wild-type SF3B1 is a 
non-driver CYCLOPS (Copy-number alterations Yielding 
Cancer Liabilities Owing to Partial losS); in other words, 
partial loss of SF3B1 pre-disposed cells harboring this loss to 
cell death upon exposure to stimuli that further reduce 
SF3B1 expression, thus partial loss of this gene results in a 
pro-apoptotic state. The CYCLOPS dependency is distinct 
from SF3B1 dependencies targeted by current spliceosome 
inhibitors [48]. SF3B1 mutations can be seen in 80% of 
patients with MDS-RS-SLD (MDS-RS with single lineage 
dysplasia) and 40% of patients with MDS-RS-MLD 
(MDS-RS with multilineage dysplasia), with the percentage 
of BM RS often correlating directly with the SF3B1 mutant 
allele burden. The survival of patients with MDS-RS-MLD is 
inferior to that of MDS-RS-SLD, but better than that of 
patients with MDS-MLD without BM RS or SF3B1 
mutations [45]. Therefore, SF3B1 initially may represent a 
compensatory protective mutation; a middle of the road 
alteration that while enhancing the pro-apoptotic state, 
hampers progression to AML. 
U2 auxiliary factor (U2AF) 
The U2AF heterodimer plays a vital role in defining 
functional 3′ splice sites in pre-mRNA. Mutations are present 
in the U2AF complex, particularly in the U2AF1 gene 
(which encodes for the U2AF35 subunit) in blood disorders 
and other human cancers [49]. The U2AF complex consists of 
65kD and 35kD subunits, and, as a heterodimer, is one of the 
best-characterized splicing factors in higher eukaryotic cells. 
Multiple mutations in both U2AF65 and U2AF35 have been 
reported to associate with blood disorders, particularly MDS 
[7, 44]. Several studies using unbiased genomic analysis of 
isogenic human and murine cells expressing ectopic mutant 
or wild-type U2AF1 have revealed that mutations in U2AF1 
consistently alter the 3′ splice site (SS).  
U2AF1 mutations are associated with abnormal splicing of 
genes involved in functionally important pathways, including 
cell cycle progression and RNA processing, and with 
mutations in epigenetic regulators ASXL1 and DNMT3A [44]. 
These mutations are most frequent in more proliferative 
phenotypes, including MDS/MPN and high-risk MDS [50]. 
U2AF1 (U2AF35) together with SRSF2 mutations are 
associated with refractory cytopenia with multi-lineage 
dysplasia (RCMD), refractory anemia with excess blasts 
(RAEB), and to high-risk leukemic transformation. 
Moreover, U2AF1 and SRSF2 present mutations associated 
with shorter survival [51].  
Ilagan et al., has revealed that downstream targets of 
U2AF1 mutations may promote pathogenesis through 
RNA & DISEASE 2019; 6: e1531. doi: 10.14800/rd.1531; © 2019 by William L. Blalock, et al. 
http://www.smartscitech.com/index.php/rd 
Page 7 of 17 
Table 1. Heterogeneous Ribonuclear Proteins (hnRNP) and Their Functions 
hnRNP Protein Function 
hnRNPA/B Consists of A0, A1, A2/B1 and A3. They are important for mRNA translation, splicing and localization of A2RE/RTS element 
containing transcripts. Also directs miRNAs to exomes for cellular export (requires sumoylation). A3 binds single-stranded 
telomeric DNA.  
hnRNP C Members of this family can oligomerize, due to a leucine zipper in the auxiliary domain. This feature allows hnRNP C members to 
bind unstructured RNAs and sort them by size. Also stimulates MYC translation.  
hnRNP D Also known as AUF1, this family is composed of four proteins that bind AU repeats and stimulate mRNA decay.  In contrast, 
binding of these protein complexes to the TERT mRNA stabilizes it.  
hnRNP E Also referred to a poly C binding proteins (PCBP). Consists of E1 (PCBP1) and E2 (PCBP2), which bind 3' UTRs to stabilize the 
mRNA. Also act in alternative splicing and stimulate the transcription of some genes. In addition, these protein complexes stimulate 
IRES-mediated translation of some transcripts. E1 and E2 control p21Waf1 mRNA half-life. The related poly C binding proteins E3 
and E4 do not fall into the classification of a hnRNP due to their constitutive cytoplasmic localization, but E3 has been demonstrated 
to be a transcriptional repressor.  
hnRNP F This protein which is similar to the hnRNP F protein works in combination with other hnRNPs to promote alternative splicing.  
hnRNP G Also referred to as RBMX, this family consists of sex-linked proteins. HnRNP G is located on the X chromosome and is 
ubiquitously expressed. A related member RBMY is a hnRNP G family member located on the Y chromosome and expressed only 
in testis. These proteins regulate splicing allowing for the inclusion of some exons or exclusion of others in diverse transcripts. 
One target is exon 10 splicing of tau transcript.  
hnRNP H This protein which is similar to the hnRNP F protein works in combination with other hnRNPs to promote alternative splicing.  
hnRNP I Also known as polypyrimadine tract binding protein (PTBP)-1, hnRNP I interacts with polypyrimidine stretches at the branch point 
region 5' to exons. It is involved in RNA stability, translation and pre-RNA processing (regulating splicing). HnRNP I also control 
alternate 5'-3' splice site usage. In addition, hnRNP I can sequester miRNAs or block access to their complementary site on the 
mRNA.  
hnRNP K Similar to hnRNPs E1 and E2, hnRNP K has multiple nuclear-cytoplasmic functions including: splicing, transcription, and silencing 
of mRNA. HnRNP K interacts with GSK3β mRNA during osteoclast differentiation.  
hnRNP L Similar to hnRNP I, hnRNP L is involved in many aspects of RNA metabolism including mRNA stabilization and translation. 
HnRNP L is also involved in inducible exon skipping.  
hnRNP M HnRNP M acts as part of the spliceosome complex and is known to regulate splicing of fibroblast growth factor (FGF)-2 mRNA as 
well as others. Similar to hnRNP Q.  
hnRNP P2 Also known as RNA binding protein fused in sarcoma/translated in liposarcoma (FUS/TLS), this hnRNP is best known for its 
association with the neurodegenerative disease amyotrophic lateral sclerosis (ALS).  
hnRNP Q Also known as SYNCRIP, hnRNP Q is associated with mRNA maturation. Three isoforms exist (Q1, Q2 and Q3) all produced by 
alternative splicing of the same transcript. Similar to hnRNP M.  
hnRNP R HnRNP R is known to enhance transcription of the fos oncogene; it is also known to regulate CAP-independent translation by 
binding to the IRES element of target mRNAs.  
hnRNP U Closely related to hnRNP R, hnRNP U is mainly involved in transcription and alternative splicing. 
Information for this table was retrieved from UniProt/SwissProt database and Geuens,T. et al. (2016). Human Genetics 135: 851-867. 
quantitative alterations in splicing related to several cellular 
pathways, enlightening the normal function of U2AF1's zinc 
finger domains. They show that specific alterations in 3’ 
splice site recognition are crucial factors that promote the 
molecular pathology of MDS and related hematological 
disorders [52]. Park et al., show that the U2AF35 mutant 
promoted the usage of a distal poly(A) site in Atg7 mRNA, 
thus generating a longer, inefficiently translated transcript. 
Decreased ATG7 led to mitochondrial dysfunction including 
genomic instability, which induces cells to acquire secondary 
mutations disposing them to transformation [53]. 
Heterogeneous ribonuclear proteins (hnRNPs) 
Heterogeneous ribonuclear proteins assist in the 
maturation of pre-mRNA primary transcripts to mature 
mRNAs during nuclear to cytoplasmic transport, and their 
subsequent translation, by influencing alternative splicing, 
mRNA stability, transport and folding [54]. There are 20 
major types of hnRNPs and several minor families that most 
likely serve as regulators of the major hnRNPs. The hnRNPs 
contain a nuclear localization sequence (NLS) and are thus, 
primarily localized to the nucleus; but this localization is 
highly dependent on post-translational modifications which 
result in cytoplasmic localization of the hnRNPs. In addition 
to the NLS, the hnRNPs contain at least one or a combination 
of four types of RNA-binding domains (RBDs): RNA 
recognition motif (RRM), RRM-like, glycine rich with an 
RGG box, or KH-domain. The specificity of RNA-protein 
binding within hnRNPs is entirely dependent on the three 
dimensional structure of the protein surrounding the RBD, 
with diversity dictated by the combination of different 
RNA-binding motifs present [54].  Many of the hnRNPs are 
known to be part of the spliceosome complex and influence 
splicing of particular mRNAs or their alternative splicing [54]. 
Binding of some hnRNPs to the 3'-end untranslated region 
(UTR) is known to stabilize some mRNAs while targeting 
the degradation of others. Moreover, some hnRNPs sequester 
specific mRNAs or suppress their translation [54]. In addition 
to the mRNAs, the hnRNPs also have major effects on 
miRNAs. Other than these processes, the hnRNPs influence 
translation of specific mRNAs as well as the process of 
internal ribosome entry site (IRES) dependent translation [54]. 
Table 1 lists some of the hnRNP types and their known roles. 
While the hnRNPs have not been directly linked to BMFDs 
or cancer, they are major regulators of alternative splicing 
and their expression is known to influence the transcription 
and translation of multiple oncogenes. In addition, hnRNP E 
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members regulate tumor suppressor p21Waf and p63 mRNA 
stability as well as the epithelial-mesenchymal transition 
(EMT). On the other hand, mutation of other hnRNPs, such 
as hnRNP P2 (FUS), are associated with neurodegeneration 
[54].   
Adenosine deaminases acting on double-stranded RNA 
(ADARs) 
 RNA editing is an important post-transcriptional 
mechanism occurring in a wide range of organisms, which 
alters the primary RNA sequences through the 
insertion/deletion or modification of specific nucleotides. In 
humans, the most common type of RNA editing is mediated 
by the ADAR enzymes converting adenosine into inosine, 
which is interpreted by the cellular machinery as guanosine, 
within dsRNA coding and noncoding regions of the primary 
transcript. A-to-I RNA editing within mRNAs and ncRNAs 
(long ncRNA and miRs) contributes to increases in the 
human RNA/protein landscape [55]. A-to-I RNA editing 
events within pre-mRNAs can generate or destroy splice sites 
and alter codons thus increasing proteome diversity. Other 
than modifying mRNAs at splice sites and coding regions, 
modification at the 5’ and 3’ untranslated regions (UTRs) 
can alter translation and stability of the mRNA, respectively. 
In addition, modifications of miRNAs or other ncRNAs can 
alter their target specificity or function. Recently, it has been 
reported that the A-to-I RNA editing frequency is massively 
increased from mouse to human [56]. Fascinatingly, in 
humans, most A-to-I RNA editing events (≥90%) occur 
within Alu inverted repeats, located preferentially in 
gene-rich regions.  
In mammals, there are three highly conserved members of 
ADARs, ADAR (also known as ADAR1 or DSRAD), 
ADARB1 (ADAR2) and ADRB2 (ADAR3). The ADAR 
enzymes share similar domain structures: dsRNA-binding 
domains (RBDs), three in ADAR1 and two for ADAR2 and 
ADAR3 and a catalytic deaminase domain at the C terminus 
[57]. A-to-I RNA editing provides a powerful mechanism for 
fine-tuning the gene transcripts playing an essential role 
during development as shown by Adar1-/- and Adar2-/- 
knockout mice, which are embryonic or post-natally lethal, 
respectively [55, 57].  
The ADAR proteins work as homo- and heterodimers and 
the altered expression/activity of these RNA modifiers likely 
contributes to the alterations in splicing observed in 
hematologic malignancies. Specifically, ADAR1 plays an 
essential role in embryonic development, especially within 
the hematopoietic lineages [58]. Post-natal deletion of ADAR1 
in normal hematopoietic cells selectively depleted 
hematopoietic progenitor cells compared with more primitive 
cells [59]. Moreover, it has been shown that ADAR1-deficient 
hematopoietic stem cells (HSCs) were unable to reconstitute 
irradiated recipients or form differentiated cell colonies [59]. 
Indeed, ADAR1 in hematopoietic stem cells controls both 
type I and II interferon-inducible transcripts and prevents 
apoptosis [60]. More recently, it has been shown that ADAR1 
editing activity is essential also for normal erythropoiesis as 
Adar1-deficient erythroid cells display a profound activation 
of innate immune signaling and high levels of cell death [61]. 
Given the biological relevance of RNA editing in mammals 
it has been postulated that its deregulation could be linked to 
a variety of human disorders. In particular, RNA editing has 
been documented in several human cancers even though only 
recently a real connection between a RNA editing and cancer 
has been shown. One of the first cancers to be associated 
with altered A-to-I RNA editing was acute myeloid leukemia 
(AML) [62]. AML is a fast growing form of leukemia 
affecting the myeloid line of blood cells. The authors 
reported that in low-differentiated CD34(+)/CD117(+) blasts 
isolated from acute myeloid leukemia patients, the PTPN6 
transcript was abnormally edited at multiple sites leading to 
an aberrant PTPN6 transcripts with an altered SH2 domain 
which inhibited the PTPN6 protein from acting as tumor 
suppressor gene [62]. It has been demonstrated that ADAR1 is 
also involved in chronic myeloid leukemia. Indeed, Wang 
and collaborators reported that ADAR1 is required for 
Bcr-Abl leukemia cell survival in vivo and that silencing 
ADAR1 results in a rapid leukemic cell loss [63]. These 
studies elegantly uncover the role of ADAR1 in myeloid 
leukemia cells and indicate ADAR1 as a promising 
molecular target for CML-directed therapeutic interventions 
[63]. While ADAR1 seems to play a major role in disease 
affecting hematological compartment recently a role for the 
ADAR2 enzyme has also been recently demonstrated. 
Chronic lymphocytic leukemia (CLL), is characterized by B 
cells growing in an uncontrolled manner with patients 
showing a down-regulation of important tumor suppressor 
microRNAs miR-15a and miR-16-1, miRNAs that are 
controlled by ADAR2 [64]. 
RNA helicases 
Many of the processes in which the above mentioned 
proteins are involved require the unwinding of RNA-RNA 
duplexes or RNA-DNA heteroduplexes. This requires the 
activity of RNA helicases, most of which are classified as 
either DEAD-box (DDX) or DEAH-box (DHX) helicases 
based on a conserved sequence in the helicase domain [65]. In 
addition, other RNA helicases possessing variations of these 
sequences or more primative RNA helicases are also present 
in humans. In general these enzymes unwind the RNA 
secondary structure to aid in diverse processes: splicing, 
translation initiation, pre-mRNA processing, transcription, 
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Table 2. A Selection of RNA Helicases and Their Function 
RNA Helicase Function 
DDX1 DDX1 is an RNA helicase acting on RNA-RNA and RNA-DNA duplexes.  It may be involved in DNA double-strand break repair of 
actively transcribed regions of DNA. Act as a co-activator of NF-κB dependent transcription by associating with RELA. May also be 
involved in 3’-end cleavage and polyadenylation during pre-mRNA processing. This gene is often found amplified in cancer with that 
of MYCN.  
DDX2 Also known as eIF4A-I or DDX2A, DDX2 interacts with other translation initiation factors to favor translation initiation by binding as 
a complex to the 5'-end of the mRNA and assisting ribosome binding. Often overexpressed in diverse cancers including melanoma and 
hepatocellular carcinoma.  
DDX5 Also known as RNA helicase p68, DDX5 is involved alternative regulation of pre-mRNA splicing.  It participates in altered splicing 
of c-H-ras. Its helicase activity is required for the inclusion of tau exon 10 and it acts as a transcriptional co-activator for the estrogen 
receptor (ESR1) and the androgen receptor (AR). It synergizes with DDX17 and SRA1 RNA to activate MYOD1 transcriptional 
activity during skeletal muscle differentiation. It also acts as a transcriptional co-activator for p53 and is involved in the p53 DNA 
damage response and p53 dependent apoptosis. Moreover, it also acts as a transcriptional co-activator for RUNX2 and is involved in 
osteoblast differentiation. Can be involved in promotor specific transcriptional repression through a mechanism likely involving 
HDAC proteins.  
DDX6 Also known as p54/RCK, DDX6 regulates the translation of mRNA by decapping specific mRNAs, resulting in the degradation of 
these transcripts.  
DHX9 Also known as RNA helicase A, DDX9 acts on dsDNA and dsRNA to alter the secondary structure allowing for protein-nucleic acid 
interaction.  In complex with CBP and RNA pol II it initiates transcription in certain genes. DDX9 is also a component of the 
CRD-mediated complex that stabilizes c-myc transcripts. Along with DDX5, DDX9 inhibits 3’transcriptional termination of circadian 
target genes. DDX9 positively regulates HIV LTR-mediated transcription and gene expression, interferes with BRCA1 function when 
overexpressed, and up-regulates p16 expression. DDX9 is often overexpressed in lung carcinoma.  
DDX10 DDX10 has a possible role in ribosome biogenesis. It is involved in the Inv 11(p15q22) observed in therapy related AML and MDS.  
This inversion results in a DDX10-NUP98 fusion protein.  
DDX17 Exist as p72 or p82 isoforms. Transcriptional co-activator for the estrogen receptor ESR1. Act in synergy with DDX5 to stimulate 
MYOD1 transcriptional activity and is likely involved in skeletal muscle differentiation. Associates with U1 snRNP and promotes 
alternative splicing.  
DHX32 Plays a role in pre-mRNA splicing and is often down-regulated in ALL.  
DDX43 Also known as HAGE. Its role is unknown. Up-regulated in diverse cancers.  
DDX47 DDX47 associates with pre-rRNA precursors and has a role in their processing and ribosome biogenesis. Likely has a role in mRNA 
splicing and stability. Associates with the E1E4 protein of HPV type 16. Is highly involved in apoptosis.  
DDX48 DDX48 which is highly similar to DDX2A is also known as DDX2B or eIF4A-II.  It is a core component of the splicing-dependent 
exon junction complex (EJC). Involved in translational enhancement of spliced genes by stabilizing spliced mRNA at the exon-exon 
junctions. Modifies the splicing of BCL2L1/BCL-X inhibiting the formation of BCL-Xs. Found as a common member of the nuclear 
matrix. It is involved in cranial-facial development and is often found up-regulated in gastric cancer.  
DDX53 Also known as CAGE. Its function is unknown. 
Information for this table was retrieved from UniProt/SwissProt database and Abdelhaleem,M. (2004). Biochimica et Biophysica Acta 1704: 
37-46.
ribosome biogenesis and RNA-protein nuclear-cytoplasmic 
transport. These proteins are more often than not 
overexpressed in diverse cancers. Others such as DDX10 and 
DHX32 have been shown to be involved in chromosomal 
alterations in leukemia or down-regulated in ALL, 
respectively [65]. Table 2 lists some of the known RNA 
helicases and their roles. 
rRNA processing and ribosome biogenesis 
Ribosome biogenesis is one the most costly processes of 
the cell in terms of energy, and the cell goes to great lengths 
to maintain strict control over the process. The final product 
results in a functional ribosome, which in eukaryotes consists 
of 40S and 60S subunits contains 4 species of processed 
ribosomal RNA (18S, 28S, 5.8S and 5S) and 79 ribosomal 
proteins (RPs) [66-68]. The mature 40S subunit consists of 18S 
rRNA and 33 RPs, while the 60S subunit consists of 28S, 
5.8S and 5S rRNAs and 43 RPs. In addition to these, over 
200 other non-ribosomal proteins and 75 snoRNAs are 
required for ribosome synthesis.  
Ribosome biogenesis is a highly dynamic process in 
which, transcription of the pre-rRNAs, 
processing/modification of the pre-rRNAs, association of 
RPs to the pre-rRNAs, proper folding of the pre-rRNAs and 
transport of the maturing ribosomal subunit to the cytoplasm 
are all combined [66, 67]. The process initiates with the 
synthesis of the rRNAs. While the 5S rRNA is transcribed by 
RNA pol III from multiple genes into the nucleoplasm and 
then migrates to the nucleolus, the 18S, 5.8S and 28S rRNAs 
are transcribed by RNA pol I as a single precursor RNA from 
tandem repeats of the gene into the nucleolus. The initial 
pre-rRNA transcript maintains a secondary structure at the 
newly synthesized 5’-end which acts as a platform for the 
binding and association of an initial set of RPs. As this 
portion of the pre-rRNA contains what will become 18S 
rRNA of the 40S subunit, the RPs associating with the 5’-end 
are small RPs or RPSs. The initial binding of the RPSs and 
the processing at the external transcribed spacer (ETS) as 
well as modifications of the rRNA by ribose methylases 
(C/D box snoRNPs) and polyuridylases (H/ACA box 
snoRNPs) energetically favors an rRNA structure that forms 
a platform for the next round of RPs to associate [66, 67]. At 
the same time, processing of the 5’-end of the 18S rRNA is 
being conducted, processing and cleavage at the 3’-end of the 
18S rRNA is occurring within the internal transcribed 
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sequence (ITS1) to liberate the assembling 40S subunit from 
the 60S subunit that is now being assembled and beginning 
to be transported to the cytoplasm [66, 67]. Virtually the same 
process occurs for the formation of the maturing 5.8S and 
28S with the ITS2 (between 5.8S and 28S sequences) 
initially beginning to be cleaved and processed before 
cleavage and processing of the 3’ ETS of the pre-rRNA. At 
this point, the associating RPs are RPLs as they will become 
part of the 60S subunit. The process, marked by rounds of 
rRNA processing and folding and rounds of RP association, 
continues to occur until the last of the RPs for each subunit 
are finally incorporated in the cytoplasm. Due to the ability 
of RNA to assume diverse energy structures at equilibrium, 
diverse modes of assembly can be occurring simultaneously 
including the synthesis of kinetically dead-end products that 
are aborted and targeted for degradation and recycling by the 
TRAMP4/5 complex [67].  
In addition, to the RPs incorporated into the ribosome and 
the rRNA modifying proteins, a number of proteins associate 
with the maturing ribosome in the nucleus to ensure that the 
ribosome does not prematurely assemble. Once exported into 
the cytoplasm these chaperons disassociate from the 
ribosomal subunits, allowing for ribosomal subunit assembly 
and the association of mRNA and translation initiation 
factors (IFs) [21, 66, 67, 69].  
Alteration of ribosome biogenesis can have mild to dire 
consequences depending on the defect and its penetrance, 
and often affects tissues which have the greatest rates of 
proliferation and turn-over, including the skin and 
hematopoietic precursors in the bone marrow, especially 
erythroid precursors.  
Ribosomal subunit proteins (RPs) 
The ribosomal subunit proteins are divided into two 
groups based on the ribosomal subunit of which they are a 
part. Those associating with the 40S subunit are referred to 
as RPSs or small ribosomal subunit proteins, while those 
associating with the 60S subunit are referred to as RPLs or 
large ribosomal subunit proteins [66, 70]. Several lines of 
evidence indicate that the main purpose of the RPs is to 
stabilize rRNA folding and structure, thus assisting in 
processing: (i) the RPs are RNA-binding proteins which are 
dependent on RNA structure and conformation, (ii) there are 
very few protein-protein interactions between the RPs, (iii) 
while many of the RPs possess a tail which inserts into the 
ribosome core, the core is mostly hollow, with the exception 
of the rRNA species, and these protein tails do not interact 
with the mRNA substrate [66]. 
In contrast, the RPs may have other trans-regulatory 
functions. It has been demonstrated that certain RPs 
preferentially regulate the expression of NF-κB, p53, p21, 
Myc and some nuclear receptors. Others have been 
demonstrated to bind to the untranslated regions of mRNAs 
resulting in changes in mRNA stability or other 
transcript-specific outcomes. RPL40 is required for the 
efficient translation of many stress response proteins as well 
as vesticular stomatitis virus (VSV) mRNA, and RPL38 has 
been shown to affect the translation of some homeobox 
mRNAs [70]. 
The best known ribosomopathy is Diamond-Blackfan 
Anemia (DBA; see above). While some forms of DBA result 
from a complete loss of a RP, the majority of cases result 
from mutations that create a haploinsufficiency of the 
affected RP. Mutations in RPS7, RPS10, RPS17, RPS19, 
RPS24, RPS26, RPS27, RPS29, RPL5, RPL11, RPL26, 
RPL27, RPL35A and deletion of RPL15 as well as other 
novel mutations in RPL3L, RPL6, RPL7L1T, RPL8, RPL13, 
RPL14, RPL18A and RPL31 have been reported. 
Approximately 50% of DBA patients contain mutations in 
either RPS7, RPS10, RPS17, RPS19, RPS24, RPS26, 
RPS29, RPL5, RPL11, RPL26, RPL35A or GATA; RPS19 
mutations alone make-up 25% of the cases of DBA [19]. In 
addition to DBA, 5q-syndrome in MDS presents a 
haploinsufficiency of RPS14 [71]. 
Two of the first RPs to associate with the pre-rRNA at the 
5’-end are RPS7 and RPS24, which are required to initiate 
processing and cleavage of the pre-rRNA at the 5’-ETS; thus 
low levels of these proteins block or retard rRNA processing 
resulting in failed maturation of the 5’-end of the 18S rRNA. 
Similarly, depletion of the levels of RPS17 and RPS19, 
which are required for ITS1 cleavage, result in failed 
processing of 3’-end of the 18S rRNA. This failed ribosome 
Figure 1. RNA splicing mechanisms increase the coding capacity of the genome. (A) Splicing and/or 
alternate splicing of the primary transcript lead to the production of diverse protein isoforms that may differ in 
tissue expression, cellular localization, physical properties and function. Alterations in expression or mutations in 
proteins involved in these processes have been found in most bone marrow failure disorders and contribute to 
the pathology of the disorder and the progression to AML. (B) RNA editing can induce amino acid changes that 
alter protein coding (as shown); alter the 5’ UTR or 3’ UTR of mRNAs changing their translation rates or stability; 
respectively; alter the specificity of miRNA, and thus change its target, or alter the miRNA recognition sites in 
targets allowing the target RNA to by-pass processing. More often than not RNA editing alters splice recognition 
sites and thus changes mRNA splicing site selection. 
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biogenesis results in a pro-apoptotic state in affected cells 
apparently through the augmentation of p53 expression [70]. 
The expression of RPs as well as RNA pol I and III is 
under the translational control of mTOR and the eIF2α 
kinases (PKR, PERK, GCN2 and HRI) in response to growth 
factors, nutrient conditions and stress. Under growth 
conditions mTOR activity favors the enhanced expression of 
both RPs and the RNA polymerases resulting in sufficient 
expression of the components necessary for the ribosome 
biosynthesis. Under stress conditions, reduced mTOR 
activity and phosphorylation of eIF2α results in reduced 
translation and expression of the polymerases as well as the 
RPs [2, 70]. Interestingly, under the conditions of 
haploinsufficiencies of the RPs, the process of pre-rRNA 
maturation is altered resulting in an increasing pool of 
unassimilated RPs. These free RPs, including a complex 
consisting of 5S rRNA, RPL5 and RPL11, have been shown 
to associate with MDM2, the p53 ubiquitinase, and sequester 
it from p53, thus enhancing p53 protein stability [20, 70]. In 
addition to this mechanism, other mechanisms, including 
DNA double-strand (ds) breaks due to replication stress and 
AMPK activation, due to ATP depletion, have been proposed 
to lead to increased p53 expression. Thus, the enhanced level 
of p53 places the affected cells into a pro-apoptotic state 
where they are hypersensitive to certain stresses [70].  
Figure 2. Ribosome biogenesis requires the simultaneous synthesis of rRNA, post-transcriptional modification of rRNAs, 
ribonucleoprotein assembly and nucleo-cytoplasmic transport. The diverse classes of proteins and ribonuclear protein complexes 
and where they intervene in the process of ribosome biogenesis are shown. The proteins involved facilitate the processing, modification 
and packaging of the rRNA species into the 40S and 60S subunits. Other proteins maintain these subunits separate until they have been 
transported to the cytoplasm where the combine to for the 80S ribosome.  
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Other than enhanced p53 expression, other mechanisms 
may explain the pro-apoptotic and poor proliferative state 
observed following the loss or reduced expression of RPs. 
Loss of RPL5 or RPL11 was shown to lead to reduced cyclin 
expression, and therefore, reduced proliferation. 
Additionally, cells deficient in RPS19 and RPL11 were 
demonstrated to be predisposed to oxidative stress [70]. In 
addition, an innate immune component has been observed. 
RP loss/reduction enhances the expression of innate immune 
genes including interferon and TNFα, which is known to 
contribute to the hematopoietic failure in RPS19 deficiency, 
likely through IRES-mediated translation [20]. Moreover, RP 
depletion affects the insulin signaling pathway [70]. In fact, 
certain DBA patients present with symptoms similar to 
insulin resistance observed in pre-diabetic patients. Such a 
finding may relate to the constitutive activation of PKR, a 
stress-activated/innate immune eIF2α kinase that is key in 
phosphorylating the insulin response substrate (IRS1) 
resulting in insulin resistance [72, 73]. Interestingly, PKR is 
also required for the pro-apoptotic effects of interferon and 
TNFα [2, 15]. 
Shwachman-Bodian-Diamond syndrome protein (SBDS) 
About 90% of patients presenting with 
Shwachman-Diamond anemia have a mutation in the SBDS 
protein. The gene encoding SBDS is located on chromosome 
7q11 and is immediately adjacent to its pseudogene, SBDSP, 
which is 97% identical to SBDS but contains deletions and 
nucleotide changes that prevent the expression of a 
functional protein. Interestingly, it is a recombination with 
this pseudogene that results in SBDS mutations in 75% of 
patients [21]. The SBDS gene encodes a 250 amino acid (29 
kDa) protein that contains no known structural domains. The 
exact function of SBDS is unclear, but it apparently has a 
role in both ribosome biogenesis and genomic stability. 
SBDS is expressed ubiquitously in tissues and is localized 
throughout the cell with a particular preference for the 
nucleolus where ribosome biogenesis occurs. Mouse 
knock-out models and the fact that a common early 
truncation mutation at nucleotide 183 (TA>CT) is observed 
only in individuals heterozygous for the defect, suggest that 
loss of SBDS is embryonic lethal [21].  
As is the case for most bone marrow failure disorders, the 
number of CD34+ hematopoietic cells in the bone marrow is 
reduced, and these cells show a reduced proliferative and 
colony forming capacity when compared to normal CD34+ 
hematopoietic cells. In addition, elevated p53 expression and 
increased apoptosis are observed in the bone marrow of SDS 
patients [21].  
SBDS associates with Nip7, a 60S ribosomal subunit 
assembly factor and eIF6 associated with the 60S ribosome. 
In the assembling 60S ribosomal subunit, eIF6 serves in the 
proper maturation of the subunit and to inhibit the premature 
assembly of the 40S and 60S subunits to form the 80S 
ribosome. Mutational rescue data suggest that SBDS serves 
to disassociate eIF6 from the 60S subunit once it reaches the 
cytoplasm. This occurs by the SDBS-dependent recruitment 
of the cytoplasmic GTPase EFL1 to the eIF6-60S subunit 
complex. EFL1 promotes the dissociation of eIF6 from the 
60S subunit allowing for 80S assembly [21, 69]. Thus, during 
ribosome biogenesis reduced expression of SBDS hampers 
the dissociation of eIF6 which has a much larger influence in 
cells that are more translationally active. 
In addition to its role in ribosome biogenesis, SBDS has 
also been shown to associate with microtubules during 
mitosis. SBS patients often show increased incidence of 
mitotic abnormalities, with multi-polar spindles and 
centrosomal amplifications. Data from human fibroblasts in 
which SBDS was knocked-down recapitulated these mitotic 
findings, but only after two weeks; thus, it is unclear if these 
observations in patients are a direct result of SBDS reduction 
or a result of other changes downstream caused by prolonged 
reduction of SBDS [21].  
H/ACA snoRNP complex 
The H/ACA complex is involved in: the maintenance of 
telomeres, the pseudouridylation of rRNAs, ribosome 
biogenesis, splicing of small nuclear RNAs, and direct 
microRNA processing [74, 75]. The complex consists of a 
protein component which is directed to its target by the RNA 
component. The protein component consists of four proteins: 
dyskerin (DKC1), NOP10, NHP2 and GAR. Dyskerin is a 
pseudouridylase containing a catalytic domain and a distal 
PUA domain. NOP10 is an elongated protein that binds and 
stabilizes DKC1; while NHP2 is a RNA binding protein 
which recognizes and binds RNAs with a K-turn or K-loop 
stem-loop structure. Finally, GAR, a small basic protein, 
provides stereo-spacial regulation to the active complex [76, 
77]. The small nucleolar RNAs (snoRNAs) associate with the 
PUA domain in DKC1 and the K-binding domain of NHP2. 
The sequences complementary to the target to be modified, 
present in the loops, flank the catalytic pocket of DKC1. In 
some cases, two stem-loop structures support the 
pseudouridylation of multiple targeted uridines in proximity 
to one another. The binding of the H/ACA snoRNP protein 
complex to the snoRNA unwinds and opens the guide 
RNA-target RNA complex to favor the accessibility of the 
target uridine to the DKC1 catalytic site, where DKC 
catalyzes the formation of a C5 glycoside isomer of uridine 
[75, 76, 78].   
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Unlike the hnRNPs whose RNA targeting is dependent on 
the proteins present in the complex and their respective 
RBDs, the H/ACA snoRNP complex has a finite protein 
component and thus the diversity of its targets is dictated by 
the associated guide RNAs [75, 76, 78]. These guide RNAs 
(snoRNAs or scaRNAs) all contain closely related H-box and 
ACA-box sequence elements and are composed of one or 
more stem-loop structures which are interrupted by an 
internal bulge with sequences complementary to those 
sequences flanking the site of pseudouridylation in the target 
(the exception is telomere RNA which is a snoRNA but does 
not direct pseudouridylation) [76, 78]. The pseudouridylation of 
rRNAs, targeted by the H/ACA RNP complex, occurs in 
regions critical for ribosome activity such as the decoding 
center or peptidyl transferase domain. Pseudouridylation 
affects translation fidelity, stop codon usage and is required 
for IRES-mediated translation [76, 78, 79]. Alterations in the 
H/ACA snoRNP complex is most prominent in leukemias 
but is also altered in some solid tumors, including: prostate, 
head and neck, and non-small cell lung cancer [79].  
The snoRNAs are derived from intron sequences 
spliced-out of primary transcripts encoding "host proteins". 
Hypermethylation of the DNA encoding these introns can 
result in decrease expression of specific H/ACA snoRNAs. 
In addition, mutation of these sequences can affect target 
binding of the H/ACA RNP complex. These H/ACA 
snoRNAs are highly mobile elements and a translocation 
along with a mutation that changes the target specificity of 
the guide sequences can result in an increase in the target 
repertoire, thus the number of targets is infinite [76, 78]. The 
H/ACA snoRNAs are also involved in chromatin structures 
and the iRNA machinery.  
While the expression of H/ACA snoRNAs is typically 
reduced in disease, mutations in the H/ACA proteins (DKC1, 
NOP10 and NHP2) have been associated with the rare bone 
marrow failure syndrome, dyskeratosis congenita (DC) [80]. 
The H/ACA snoRNP protein components are also required 
for the correct processing and trafficking of TERC, the RNA 
component of the telomerase reverse transcriptase 
holoenzyme (TERT). Interestingly, in a zebrafish model, 
Pereboom, et al., demonstrate that NOP10 loss can give rise 
in the cytopenia phenotype in DC through the destabilization 
of the 40S ribosomal subunit as a result of 18S rRNA defects 
resulting in the cooperation of RPS7 with MDM2 and the 
stabilization of p53 in HSCs [24]. This hematopoietic failure 
could be rescued by the loss of functional p53. These data 
revealed that the effect of deficiency of H/ACA RNP 
complex genes on hematopoiesis is mediated by p53. It has 
always been debated as to whether DC is a disease related to 
ribosome biogenesis or loss of telomere maintenance. While 
much of the phenotype likely does result from lack of 
telomere maintenance, the data presented by Zhang et al. and 
Pereboom et al., demonstrated that the associated anemia and 
hematopoietic failure results primarily from impaired rRNA 
processing and ribosome biogenesis and the subsequent 
stabilization of p53, common features also seen in DBA and 
SDS [23, 24]. 
Conclusions 
The bone marrow failure disorders as a whole have shed 
significant light on general mechanisms involved in clonal 
selection and progression to cancer. Other than direct DNA 
mutations or epigenetic modifications, many of the 
alterations observed that occur in these diseases and their 
progression to AML involve intermediates of RNA 
processing and ribosome biogenesis, which influence protein 
expression and isoform selection, as well as genome stability. 
The result is a pro-apoptotic atmosphere with the enhanced 
possibility for further survival mutations, resulting in clones 
resistant to the safeguards of normal cellular growth and 
differentiation. While many of these processes are coming to 
light, more in-depth analyses of these processes, their role 
and how they are regulated, is needed in order to define 
therapeutic targets for disease intervention. Such knowledge 
will require a major input from basic scientific research.  
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